Heres how Retatrutides side effect profile compares to FDA-approved alternatives
[2] In SURPASS-1, Mounjaro (15 mg) demonstrated a mean weight reduction of 22.5% compared to 3.0% with placebo at 52 weeks
In fact, caffeine's independent mild appetite-suppressing effect may feel complementary to your GLP-1 therapy, though its effects are temporary compared to your medication's sustained action
If you are considering or currently using BPC-157 or TB-500, we recommend seeking medical advice first to avoid risking complications
Using anything else is an unnecessary risk
National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 19902021, and forecasts up to 2050